Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2003

View Archived Issues

Three series of antitumor agents prepared and tested at Synta

First-quarter development at Esperion

Roche patents retinoid receptor agonists for emphysema and other uses

Novel tyrosine kinase inhibitors under study at Merck & Co.

GSK researchers describe new beta2-adrenoceptor agonists for use in respiratory disorders

New GSK-3 inhibitor with utility in diabetes therapy

Aventis scientists identify novel protein kinase inhibitors

Novo Nordisk and Boehringer Ingelheim describe new histamine H3 receptor modulators

New antidiabetic agents in early development at Merck KGaA

Novel modulators of LPA receptors and their use in cancer, wound healing, etc.

New iGluR5 antagonists in Lilly development pipeline

Procyon completes acquisition of Pharmacor

EyeTech enters Xalatan commercialization agreement with Pfizer

Arrow's RSV compound enters preclinical testing

Initiation of phase I/II study of CG-7870 plus radiation in early-stage prostate cancer

Diatos licenses European rights for Super-Leu-Dox

ISIS-23722 selected for clinical development

Microscience develops oral anthrax vaccine

FDA approves Oxycyte clinical protocol

Positive results from second phase III trial of immediate-release indiplon

Phase II Oxytrex study completes enrollment

Ilomastat successful in treating exposure to mustard gas

FTY-720 protects rats against experimental autoimmune encephalomyelitis

Neurokinin NK1 receptor antagonism prevents cytokine-mediated liver injury

NIH licensing opportunity: method of promoting T-cell migration to tumor vasculature

sFRP and peptide motifs that interact with sFRP and methods of use available for licensing from NIH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...